Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesInfectious DiseaseAllCareAdvantage nonpreferred urinary antibiotics …
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 133.2

    Nonpreferred Urinary Antibiotics Prior Authorization

    Customize your policy alerts

    Sign up for allcareadvantage Policy 133.2 alerts

    Get alerted when Policy 133.2 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization criteria for covering nonpreferred urinary antibiotic agents (gepotidacin, pivmecillinam, sulopenem etzadroxil-probenecid) for treatment of uncomplicated urinary tract infections; applies to AllCare Advantage members and prescribing providers seeking coverage.

    Policy Summary
    Payerallcareadvantage
    PolicyNonpreferred Urinary Antibiotics Prior Authorization
    Policy CodePolicy 133.2
    Change TypeNo material change
    Effective DateJun 26, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2027
    Key ActionSubmit prior authorization with documentation of uncomplicated UTI and either ID prescriber or urine culture showing susceptibility plus evidence of resistance or contraindication to preferred antibiotics.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3agents included
    Up to One fillinitial approval
    FDA dosingquantity limits
    Adults ≥18age requirement

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Nonpreferred Urinary Antibiotics

    inv-01: Initial authorization criteria

    Covered when ALL of the following are met:

    Initial criteria: 1) Request is not a renewal (if renewal, use renewal criteria). 2) Member is age ≥18 years OR if <18 the medication is appropriate for the age per FDA approved labeling, CMS-approved compendia, or other clinical treatment guidelines. 3) Submitted documentation supports a diagnosis of uncomplicated urinary tract infection (uUTI). 4) Medication is prescribed by an Infectious Disease (ID) specialist OR there is a documented urine culture demonstrating the uUTI organism is sensitive to the requested medication AND there is documented resistance or contraindication to preferred antibiotics for uUTI. 5) Alternatively, approval if there is documentation that the medication was started while the member was an inpatient. Approval length: up to one fill.all

    If any of the above fail, deny or forward to MD for review as specified.

    inv-02: Renewal criteria

    Renewal requests covered when ALL of the following are met:

    Renewal criteria: 1) Member met the initial criteria. 2) Documentation in the chart supports a positive clinical response to the requested treatment. 3) Documentation supports treatment extension or retreatment per FDA approved labeling, CMS-approved compendia, or other clinical treatment guidelines. Approval length: up to one additional fill when criteria met.all

    If renewal criteria are not met, deny.

    Requests for members 18 years of age must include supporting evidence that the medication is appropriate for the patient’s age when the member is under 18. Appropriateness for pediatric use must be documented by one of the following: FDA‑approved labeling, a CMS‑approved compendium, or recognized clinical treatment guidelines that support the agent’s use in that age group. If such supporting labeling or compendia/guideline references are not provided for patients <18, the request will be forwarded for MD review or will not meet criteria.

    Use will be considered not meeting criteria (and will be denied) when documentation does not support an uncomplicated urinary tract infection (uUTI), or when neither an Infectious Disease (ID) specialist prescription nor a qualifying urine culture is provided. Specifically, requests lacking: (1) documentation of an uncomplicated UTI diagnosis, (2) an ID prescriber or (3) a urine culture demonstrating the uUTI organism is sensitive to the requested medication plus evidence of resistance or contraindication to preferred uUTI antibiotics, should be denied. Additionally, requests that rely on inpatient initiation but do not document that the medication was started while the member was an inpatient will not meet criteria.

    Provider Requirements and Authorization Workflow

    Prior Authorization

    Prior authorization required; initial approvals up to one fill

    Prior authorization is required for nonpreferred urinary antibiotics. Initial approvals are limited to up to one fill when all initial criteria are met, including age requirements, documentation supporting uncomplicated UTI, and either an Infectious Disease (ID) prescriber or culture-based justification with documented resistance/contraindication to preferred agents; approval may also be granted if the medication was started while the member was an inpatient.

    • Initial approvals: up to one fill when criteria met
    • Criteria include: age ≥18 (or appropriate for age per FDA/CMS/guidelines if <18), documentation of uncomplicated UTI, and either ID prescriber OR documented culture showing susceptibility plus resistance/contraindication to preferred agents; inpatient-start documentation is an alternative justification.
    Step Therapy

    Document resistance or contraindication when not prescribed by ID

    If the prescriber is not an Infectious Disease specialist, the request must include documentation that the infecting organism is resistant to or the patient has a contraindication to preferred antibiotics for uUTI; without this sequencing evidence, approval is not supported.

    Definitions

    uUTI (uncomplicated urinary tract infection) — definition and scope
    DefinitionClinical diagnosis of urinary tract infection in patients without structural or functional abnormalities of the urinary tract referenced in this policy as the indication for the listed agents (uUTI).
    Typical causative organismsCommonly caused by Escherichia coli and other gram‑negative organisms; policy lists E. coli, Proteus mirabilis, Staphylococcus saprophyticus, Klebsiella pneumoniae, Citrobacter freundii complex, and Enterococcus faecalis as relevant susceptible organisms for included agents.
    Age scopeAgents in this policy are indicated primarily for adults; pivmecillinam: female patients ≥18 years; gepotidacin: adults and pediatric patients ≥12 years and ≥40 kg — policy default age requirement for coverage is adults ≥18 years unless FDA labeling, CMS compendia, or guidelines support use in younger patients.
    Clinical boundaries / exclusionsApplies to uncomplicated infections only — excludes patients with structural or functional urinary tract abnormalities, and use outside age-appropriate labeling without supporting compendia/guidance may be denied or referred for MD review.
    Place in therapy

    Background

    Uncomplicated urinary tract infections (uUTIs) are commonly caused by Escherichia coli and other gram‑negative organisms. Newer oral agents included in this policy—pivmecillinam, gepotidacin, and sulopenem etzadroxil‑probenecid—are recognized options for treatment of uUTI when resistance or allergies limit use of preferred agents. Gepotidacin has a novel mechanism of action; however, its use should generally be reserved for situations where culture‑directed therapy or specialist assessment justifies its selection to avoid promoting resistance. These agents are included in the policy as nonpreferred urinary antibiotics requiring prior authorization.

    Policy Summary
    Payerallcareadvantage
    PolicyNonpreferred Urinary Antibiotics Prior Authorization
    Policy CodePolicy 133.2
    Change TypeNo material change
    Effective DateJun 26, 2025
    Last ReviewDec 18, 2025
    Next Review DateDec 18, 2027
    Key ActionSubmit prior authorization with documentation of uncomplicated UTI and either ID prescriber or urine culture showing susceptibility plus evidence of resistance or contraindication to preferred antibiotics.
    SourceLink
    On This Page
    Coverage Criteria for Nonpreferred Urinary AntibioticsProvider Requirements and Authorization WorkflowDefinitionsBackground
    • Requires documented resistance to preferred uUTI antibiotics OR documentation of contraindication to preferred agents when the prescriber is not an ID specialist.
    Documentation Required

    Provide diagnosis, culture results, susceptibilities, and resistance/contraindication evidence

    Submit clinical documentation that supports a diagnosis of uncomplicated urinary tract infection. If approval is sought based on culture-directed therapy, include urine culture results identifying the organism and antibiogram/susceptibility showing sensitivity to the requested medication. Also provide evidence of resistance or contraindication to preferred antibiotics and indicate prescriber specialty and whether the medication was initiated during an inpatient stay when applicable.

    • Documentation supporting diagnosis of uncomplicated UTI
    • Urine culture with organism identification and susceptibilities when relying on culture-directed rationale
    • Evidence of resistance or contraindication to preferred agents if not prescribed by an ID specialist
    • Prescriber specialty (ID) or documentation that medication was started as an inpatient.
    Denial Risk

    Conditions that will result in denial if criteria not met

    The request will be denied if initial or renewal criteria are not met. Triggers for denial include failure to meet age requirements (or lack of supportive FDA/CMS/guideline evidence for patients <18), absence of documentation of uncomplicated UTI, lack of an ID prescriber or a urine culture demonstrating susceptibility plus resistance/contraindication to preferred agents, and absence of inpatient-start documentation when that is the justification. Renewal requests will be denied if prior criteria were not met, there is no documented clinical response, or there is no documentation supporting extension per FDA labeling/CMS compendia/guidelines.

    • Denial triggers for initial requests: age not met without supportive labeling/compendia/guidelines, no documentation of uncomplicated UTI, no ID prescriber and no culture demonstrating susceptibility plus resistance/contraindication, or no inpatient-start documentation when relied upon.
    • Denial triggers for renewals: member did not meet initial criteria, no documentation of positive clinical response, or no documentation supporting treatment extension per FDA/CMS/guidelines.
    These nonpreferred agents are intended for uUTI when organisms are susceptible and when there is resistance or contraindication to preferred antibiotics; gepotidacin is noted as having a novel mechanism but should not be used empirically due to limited trial benefit and resistance concerns.